Name: Mouse OX40L (CD252) Protein (N-His)
Brand: InnoCyto
SKU: 605301
Price: 145 USD
Availability: InStock

Shop Now Contact

Mouse OX40L (CD252) Protein (N-His)

Purified Mouse OX40L Protein (N-His) on SDS-PAGE under non-reducing (P-) conditions. The purity of the purified protein appears to be greater than 95% based on non-reducing condition.

Biotinylated mouse OX40 (C-Fc) is coated at 2 ug/mL (200 ng/well). Mouse OX40L (N-His) can bind mouse OX40 in a dose-dependent manner with the ED50 of 2-10 ng/mL

Cat #	Size	Price	Quantity
605301	25 ug	$145
605302	100 ug	$295

Bulk/Custom

Product Details

Application	ELISA, BLI
Format	Liquid, Purified
Expression Host	CHO
Target Name	OX40L, TNFSF4, CD252, TXGP1, CD134 ligand, , Glycoprotein Gp34
Species	Mouse
Accession Number	P43488
Sources	Recombinant Human OX40L (Gln51-Leu183) with N-terminus His tag is expressed in CHO cells.
Molecular Weight	This protein has a predicted molecular weight of 19.1 kDa. Under DTT-reducing conditions, the protein migrates at approximately 25 kDa on SDS-PAGE.
Affinity Tag	N-His
Purity	>95% based on SDS-PAGE under reducing condition
Regulatory Status	RUO
Formulation	1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level	Not tested
Protein Concentration	25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling	Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Research Areas	Co-stimulation, Dendritic cells, B cells, Macrophages, T cell survival, Th1 cells, Th2 cells, Autoimmunity

Background Information

OX40 ligand (OX40L), also known as CD252 and encoded by the TNFSF4 gene, is a type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed on activated antigen-presenting cells, including dendritic cells, B cells, macrophages, and endothelial cells. OX40L serves as the cognate ligand for OX40 (CD134), a costimulatory receptor expressed on activated CD4⁺ and CD8⁺ T cells. Engagement of OX40 by OX40L delivers a potent secondary signal that enhances T cell proliferation, survival, cytokine production, and memory T cell formation, thereby amplifying adaptive immune responses.

Structurally, OX40L is a ~34 kDa protein with a short N-terminal cytoplasmic domain, a single transmembrane region, and a C-terminal extracellular TNF homology domain. Like other TNF superfamily ligands, OX40L forms stable homotrimers on the cell surface. This trimeric structure is essential for effective receptor clustering and signaling through OX40. Binding of OX40L to OX40 promotes recruitment of TNF receptor–associated factors (TRAFs) to the receptor cytoplasmic tail, activating downstream NF-κB, PI3K–Akt, and MAPK pathways that support T cell expansion and survival.

The principal ligand of OX40L is OX40 (CD134), expressed transiently on activated T cells. Through this interaction, OX40L regulates effector and memory T cell responses and can influence regulatory T cell (Treg) function. While critical for protective immunity against infections, excessive or prolonged OX40–OX40L signaling has been implicated in autoimmune and inflammatory diseases, including asthma, atopic dermatitis, systemic lupus erythematosus, and multiple sclerosis. Genetic variants in TNFSF4 have also been associated with susceptibility to autoimmune disorders.

Therapeutically, OX40L is a target in both immuno-oncology and immune-mediated disease. In cancer, agonistic strategies that enhance OX40 signaling aim to boost antitumor T cell responses, often in combination with checkpoint inhibitors. Conversely, antagonistic antibodies or biologics that block OX40L–OX40 interactions are being developed to dampen pathogenic T cell activation in autoimmune and allergic conditions. By modulating T cell costimulation, OX40L-directed therapies offer a versatile approach to either amplify or restrain immune responses depending on clinical need.

Frequently Asked Questions

Why are Recombinant Proteins expressed with epitope tags?

The majority of InnoCyto's recombinantly expressed proteins are engineered with a short, well-characterized peptide sequence (e.g., His-tag, Fc-tag, Flag-tag, or similar) fused to the protein of interest. The tag enables reliable detection, purification, or immobilization of the protein using commercially available anti-tag antibodies or affinity resins, without needing a custom antibody against the native protein.

What types of tagged proteins are best for my application?

Common tag options include His-tag (for affinity purification via Ni-NTA/IMAC and detection via anti-His antibodies), Fc-tag (for use in binding assays, ELISA capture, and dimerization studies), and Flag-tag (for high-specificity detection and immunoprecipitation). Tag choice should be based on your intended workflow — purification-focused work often favors His-tag, while functional binding or capture-based assays often benefit from Fc-tag.

Does the tag affect the protein's biological activity or binding function?

Tag placement (N-terminal vs. C-terminal) and type are selected during design to minimize interference with the protein's native folding and functional binding site, and each tagged protein is validated for activity in relevant binding or functional assays. Product pages indicate the tag location and confirm the functional validation performed for that specific protein.

Have a product or application question? Consult our FAQs or contact us.

Search Tips